A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

  • End date
    Jun 30, 2025
  • participants needed
  • sponsor
    Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Updated on 7 October 2022


This study is a randomized, Double-Blind, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of SHR1701 combined with chemotherapy in the treatment of Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. For Part 1 study,the tolerability of SHR-1701 will be evaluated and determine the recommended dose for Part 2.For Part 2 study, all enrolled patients will be randomized to 2 groups and continuously treated until the end criteria of treatment was met.

Condition Gastric or Gastroesophageal Junction Cancer
Treatment SHR-1701、CAPOX/FOLFOX, Placebo、CAPOX/FOLFOX, SHR-1701、CAPOX, Placebo、CAPOX
Clinical Study IdentifierNCT04950322
SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Pathologically confirmed diagnosis of locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ)adenocarcinoma
HER2 overexpression or amplification negative
Female or male, 18 years of age or above
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
Patients who are willing and able to provide the signed informed consent form, willing and able to comply with all the scheduled visits, study treatment, laboratory tests, and other study procedures

Exclusion Criteria

Squamous cell carcinoma, undifferentiated carcinoma, or other histological types of gastric cancer
Presence of inadequately treated CNS metastases, or uncontrolled or symptomatic active CNS metastases ,leptomeningeal disease, and/or rapid progression
Presence of uncontrolled pleural effusion or ascites despite puncture drainage within 14 days prior to randomization
More than 20% weight loss within 2 months prior to randomization
Diagnosed with other malignant tumors within 5 years prior to enrollment
Presence of any active, known or suspected autoimmune disease
Prior treatment with TGF-β inhibitor, anti-PD-1/PD-L1 antibodies, anti-PD-L2 antibodies, anti-CD137 antibodies, anti-CTLA-4 antibodies, or other drugs/antibodies
Severe, unhealed, or dehisced wounds and active ulcers or untreated fractures
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note